Is Longevity a $1.2 Quadrillion Opportunity?
SubscribeSign in
Is Longevity a $1.2 Quadrillion Opportunity?<br>Inside the healthspan revolution and the technologies, companies, and breakthroughs driving it
Peter H. Diamandis<br>May 11, 2026
149
17
Share
Article voiceover<br>0:00
-8:46
Audio playback is not supported on your browser. Please upgrade.Today I’m releasing the updated 2026 edition of my Longevity Metatrend Report, and a lot has changed since the first edition. I believe access to information like this is crucial, so I've decided to make this report available at no cost.<br>Since that first report published last year, the world’s first partial epigenetic reprogramming therapies have entered human clinical trials, AI-engineered proteins have achieved a greater than 50-fold improvement in the performance of key cellular reprogramming factors, the first genetically engineered pig organs have been successfully transplanted into living human patients, and wearable health platforms have surpassed $10 billion valuations. This field is no longer just promising. It is delivering.<br>The updated report is over 200 pages and covers everything from leading U.S. and international longevity centers, to direct-to-consumer health platforms, to the cutting-edge science of epigenetic reprogramming, immune system optimization, and organ regrowth, including profiles of over 40 companies and centers shaping the decade ahead.<br>Below, I’m sharing my Opening Thoughts from the report to give you a window into what’s inside.
MY OPENING THOUGHTS
There is no greater wealth than your health, and no greater gift science can offer humanity than an expanded healthspan. What would you do with an extra 50 years of health? How would it change your mindset about the future?<br>Longevity (more specifically, healthspan extension) is also the largest business opportunity emerging over the next decade. ARK Invest’s Big Ideas 2026 report projects that using quality-adjusted life years valued at $100,000 each, the total addressable market for longevity interventions reaches $1.2 quadrillion. The current global biotech market captures only ~0.1% of this potential.<br>Since 2012, I’ve immersed myself in the field, investing in and building companies, and devouring publications in biotech, nutrition, exercise, sleep, and AI. I’ve also had the opportunity to interview and learn from top scientists on my own Moonshots podcast, and on my stages at the Abundance Summit and my Abundance Longevity Trips.<br>The content of this Metatrend Report also stems from my work with dozens of top scientists and physicians with whom I’ve had the honor to start companies, and/or invested in their companies. The list is long, but here’s a top-level summary: Life Biosciences, Fountain Life, Lifeforce, Celularity, Lila Sciences, Insilico Medicine, Colossal Biosciences, Retro and NewLimit just to name a few.<br>I’ve also been a benefactor supporting the extraordinary work of giants in the field such as David Sinclair, PhD, George Church, PhD, the scientists at the Buck Institute, and the $101M Healthspan XPRIZE. These friends and co-conspirators have offered me a courtside seat into the speed at which this field is making progress.<br>The aim of this Longevity Metatrend Report is twofold: First, to offer a deep understanding of the current technologies, services, and companies delivering longevity services and leading research. And second, to offer a vision of where the longevity field is heading over the decade ahead.<br>This updated 2026 edition delivers significantly updated content in the realm of AI and wearables, as well as an update to company profiles reflecting the remarkable pace of progress over the past year. This report is not exhaustive by any means. My goal here remains to offer a top-level understanding of the field. It is worth noting that this report is biased towards U.S.-based services, but identifies, where possible, leaders outside the U.S. as well.<br>How Long Might We Live?
So, how long might we all live? That’s a question of significant debate, with those who laugh at targets of 120 or 150 years old, and those who believe there is no upper limit.<br>When I was in medical school in the late 1980s, I watched a documentary on the topic of “long-lived sea life” and learned that bowhead whales can live for 200 years, and the Greenland shark has an impressive lifespan of 400 to 500 years. I remember thinking, if they can live that long, why can’t we? My answer? “It’s either a hardware or a software problem, and we’re eventually going to be able to fix that.”<br>I believe that this is the decade that we conquer those hardware and software challenges, and we are in the midst of the healthspan revolution with the potential to hit “Longevity Escape Velocity” (LEV) by 2033. (This is Ray Kurzweil’s prediction, more on this shortly.)<br>Since the first edition of this report, the world’s first partial epigenetic reprogramming therapies have entered human clinical trials, AI-engineered...